Role and room for biomarkers in non-small cell lung cancer

While molecular profiling of tumor tissue from patients with advanced cancer has been ordered by physicians to assist with treatment decision making, it is important to note that the cancer theranostics literature is rampant with many improperly validated biomarkers for prognostic and/or predictive features. This review outlines commonly assessed biomarkers in non-small cell lung cancer (NSCLC) associated with a clinical benefit. Overall, there remains room for improvements in this field and the undertaking to have validated and reproducible biomarkers associated with a clinical benefit is not a trivial undertaking.